Literature DB >> 12710718

Effects of the 2-ethylthiobenzimidazole hydrobromide (bemithyl) on carbohydrate metabolism in cirrhotic rat liver.

Margarita V Kudryavtseva1, Natalia N Bezborodkina, Sergey V Okovity, Boris N Kudryavtsey.   

Abstract

The effect of the actoprotector bemithyl (2-ethylthiobenzimidazole hydrobromide) on the content of glycogen and activities of glycogen synthase, glycogen phosphorylase, and glucose-6-phosphatase was studied in the cirrhotic rat liver. The content of glycogen and its fraction was determined by a cytofluorimetric method (Kudryavtseva et al. 1974). It has been shown that in cirrhosis the content of total glycogen in hepatocytes increases about 3 times and the content of its stable fraction increases 7.5 times. The activity of glucose-6-phosphatase fell to a level as low as 25% of normal. Activities of glycogen synthase and glycogen phosphorylase in the cirrhotic liver did not differ from normal. In the cirrhotic liver, bemithyl produced a decrease of the total glycogen content which was associated with a decrease of the glycogen synthase activity and an increase of the glucose-6-phosphatase and glycogen phosphorylase activities. Thus, the results of our studies indicate a favorable effect of bemithyl on the cirrhotic liver.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12710718     DOI: 10.1078/0940-2993-00270

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  2 in total

1.  Hepatocytes of cirrhotic rat liver accumulate glycogen more slowly than normal ones.

Authors:  Natalia N Bezborodkina; Sergey V Okovity; Anna Yu Chestnova; Boris N Kudryavtsev
Journal:  Hepatol Int       Date:  2013-07-23       Impact factor: 6.047

2.  Metformin normalizes the structural changes in glycogen preceding prediabetes in mice overexpressing neuropeptide Y in noradrenergic neurons.

Authors:  Liisa Ailanen; Natalia N Bezborodkina; Laura Virtanen; Suvi T Ruohonen; Anastasia V Malova; Sergey V Okovityi; Elizaveta Y Chistyakova; Eriika Savontaus
Journal:  Pharmacol Res Perspect       Date:  2018-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.